Safety and efficacy of 1-week levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori-related peptic ulcer disease in Kashmir, India

详细信息    查看全文

• 作者：Altaf Shah (1)
  Gul Javid (1)
  Showkat Ali Zargar (1)
  Farooq Teli (1)
  Bashir Ahmad Khan (1)
  Ghulam Nabi Yattoo (1)
  Ghulam Mohammad Gulzar (1)
  Jaswinder Singh Sodhi (1)
  Mushtaq Ahmad Khan (1)
  Abid Shoukat (1)
  Reyaz Saif (1)
  
• 关键词：Antibiotics ; Compliance ; Eradication ; Helicobacter pylori ; Peptic ulcer ; Side effects
• 刊名：Indian Journal of Gastroenterology
• 出版年：2013
• 出版时间：January 2013
• 年：2013
• 卷：32
• 期：1
• 页码：32-36
• 全文大小：122KB
• 参考文献：1. Go MF. Natural history and epidemiology of / Helicobacter pylori infection. Aliment Pharmacol Ther. 2002;16:3-5. CrossRef
  2. Graham DY, Yamaoka Y. Ethical considerations of comparing sequential and traditional anti / Helicobacter therapy. Ann Intern Med. 2007;147:434-.
  3. Gisbert JP, Pajares R, Pajares JM. Evolution of / Helicobacter pylori therapy for a meta-analytical perspective. Helicobacter. 2007;12 Suppl 2:50-. CrossRef
  4. Gisbert JP, Gonzales L, Calvet X, et al. Proton pump inhibitor, clarithromycin and either amoxicillin or nitroimidazole: a meta-analysis of eradication of / Helicobacter pylori. Aliment Pharmacol Ther. 2000;14:1319-8. CrossRef
  5. Egan BJ, Marzio L, O’Connor H, O’Morain C. Treatment of / Helicobacter pylori infection. Helicobacter. 2008;13:35-0. CrossRef
  6. Croom KF, Goa KL. Levofloxacin: a review of its use in the treatment of bacterial infections in the United Sates. Drugs. 2003;63:2769-02. CrossRef
  7. Saad RJ, Schoenfeld P, Kim HM, Chey WD. Levofloxacin based triple therapy versus bismuth based quadruple therapy for persistent / Helicobacter pylori infection: a meta-analysis. Am J Gastroenterol. 2006;101:488-6. CrossRef
  8. Marzio L, Coraggio D, Capodicasa S, Grossi L, Cappello G. Role of the preliminary susceptibility testing for initial and after failed therapy of / Helicobacter pylori infection with levofloxacin, amoxicillin, and esomeprazole. Helicobacter. 2006;11:237-2. CrossRef
  9. Sanchez JE, Saenz NG, Rincon MR, Martin IT, Sanchez EG, Martinez MJ. Susceptibility of / Helicobacter pylori to mupirocin, oxazolidinones, quinupristin/dalfopristin and new quinolones. J Antimicrob Chemother. 2000;46:283-. CrossRef
  10. Chang WL, Sheu BS, Cheng HC, Yang YJ, Yang HB, Wu JJ. Resistance to metronidazole, clarithromycin and levofloxacin of / Helicobacter pylori before and after clarithromycin based therapy in Taiwan. J Gastroenterol Hepatol. 2009;24:1230-. CrossRef
  11. Rispo A, Di Girolamo E, Cozzolino A, Bozzi R, Morante A, Pasquale L. Levofloxacin in first-line treatment of / Helicobacter pylori infection. Helicobacter. 2007;12:364-. CrossRef
  12. Liou JM, Lon JT, Chang CY, et al. Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for / Helicobacter pylori infection: a randomized comparative trial with crossover design. Gut. 2010;59:572-. CrossRef
  13. Pan X, Li Y, Qiu Y, et al. Efficacy and tolerability of first line therapy with levofloxacin, amoxicillin, plus esomeprazole, rabeprazole for the eradication of / Helicobacter pylori infection and effect of CYP2C19genotype: a 1-week randomized open-label study in Chinese adults. Clin Ther. 2010;32:2003-1. CrossRef
  14. Schrauwen RW, Janssen MJ, de Boer WA. Seven-day PPI-triple therapy with levofloxacin is very effective for / Helicobacter pylori eradication. Neth J Med. 2009;67:96-01.
  15. Nista EC, Candelli M, Zocco MA, et al. Levofloxacin-based triple therapy in first-line treatment for / Helicobacter pylori eradication. Am J Gastrorenterol. 2006;101:1985-0. CrossRef
  16. Assem M, El Azab G, Rasheed MA, Abdelfatah M, Shastry M. Efficacy and safety of levofloxacin, clarithromycin and esomeprazole as a first-line triple therapy for / Helicobacter pylori eradication in Middle East: prospective, randomized, blind, comparative multicenter study. Eur J Intern Med. 2010;21:310-. CrossRef
  17. Gisbert JP, Morena F. Systemic review and meta-analysis: levofloxacin-based rescue regimens after / Helicobacter pylori treatment failure. Aliment Pharmacol Ther. 2006;23:35-4. CrossRef
  18. Norman GR, Streiner DL. Biostatistics: the bare essentials. 3rd ed. Hamilton: BC Decker; 2007.
  19. Gupta VK, Dhar A, Srinivas S, et al. Eradication of / H. / pylori in a developing country: comparison of pantoprazole versus omeprazole with norfloxacin, in a dual therapy study. Am J Gastroenterol. 1997;92:1140-.
  20. Ahuja V, Dhar A, Bal CS, Sharma MP. Pantoprazole and secnidazole with clarithromycin, amoxicillin or pefloxacin the eradication of / Helicobacter pylori in a developing country. Aliment Pharmacol Ther. 1998;12:551-. CrossRef
  21. Anderson VR, Perry CM. Levofloxacin: a review of its use as a high-dose, short-course treatment for bacterial infection. Drugs. 2008;68:535-5. CrossRef
  22. Moayyedi P, Ragunathan PL, Mapstone N, Axon AT, Tompkins DS. Relevance of antibiotic sensitivities in predicting failure of omeprazole, clarithromycin, and tinidazole to eradicate / Helicobacter pylori. J Gastroenterol. 1998;33:160-. CrossRef
  23. Nishizawa T, Suzuki H, Hibi T. Quinolone-based third-line therapy for / Helicobacter pylori eradication. J Clin Biochem. 2009;44:119-4. CrossRef
  24. Nista EC, Candelli M, Cremonini F, et al. Levofloxacin based triple therapy vs. quadruple therapy in second line / Helicobacter pylori treatment; a randomized trial. Aliment Pharmacol Ther. 2003;18:627-3. CrossRef
  25. Gisbert JP, Gisbert JL, Macros S, Moreno-Otero R, Pajares JM. Third-line rescue therapy with levofloxacin is more effective than Rifabutin rescue regimen after two / Helicobacter pylori treatment failures. Aliment Pharmacol Ther. 2006;24:1469-4. CrossRef
  26. Oqata SK, Kawakamu E, Patrico FR, Pedroso MZ, Santen MS. Evaluation of invasive and noninvasive methods for diagnosis of / Helicobacter pylori infection in symptomatic children and adults. Sao Paulo Med J. 2001;119:67-1. CrossRef
  
• 作者单位：Altaf Shah (1)
  Gul Javid (1)
  Showkat Ali Zargar (1)
  Farooq Teli (1)
  Bashir Ahmad Khan (1)
  Ghulam Nabi Yattoo (1)
  Ghulam Mohammad Gulzar (1)
  Jaswinder Singh Sodhi (1)
  Mushtaq Ahmad Khan (1)
  Abid Shoukat (1)
  Reyaz Saif (1)
  
  1. Department of Gastroenterology, Sher-i-Kashmir Institute of Medical Sciences, Soura, Srinagar, Jammu and Kashmir, 190 011, India
  

文摘

Background and Objectives There is no ideal therapy for eradication of Helicobacter pylori infection. We evaluated the efficacy and safety of 1-week triple therapy with rabeprazole, levofloxacin, and tinidazole in a metronidazole resistance prevalent region for eradicating H. pylori infection in patients with gastroduodenal ulcers. Methods This was an open-label, prospective study. Consecutive patients with endoscopy-proven duodenal or gastric ulcer and who were H. pylori-positive were treated with levofloxacin 500?mg once a day, rabeprazole 20?mg twice a day, and tinidazole 500?mg twice daily for 7?days followed by rabeprazole 20?mg OD for 8?weeks. Endoscopy was repeated 8?weeks after the end of therapy to check for ulcer healing and H. pylori status. Results One hundred and thirty-one patients with gastroduodenal ulcers (duodenal 118, and gastric 13) were included. Drug compliance was 97.7?%. The eradication rate of H. pylori by intention-to-treat analysis was 85.5?% (95?% confidence interval 79.5-1.5) (112 of 131 patients) and by per-protocol analysis was 91.8?% (95?% confidence interval 86.9-6.7) (112 of 122 patients). Adverse effects were reported in 17?%: abdominal pain in 3.05?%, metallic taste in 6.87?%, and nausea and vomiting in 4.58?%. Conclusions Levofloxacin–tinidazole-based triple therapy was highly effective and safe as a first-line regimen in Indian patients with gastroduodenal ulcer disease associated with H. pylori infection. The regimen was well tolerated.